Getting Innovations to Patients During Shutdowns Act

Kevin Mullin

Democrat · CA · Representative

Source: Congress.gov · FEC

No cosponsors on record. Bills can pass without cosponsors — this often means the sponsor introduced the bill alone, either because it's a messaging bill, a chairman's mark, or simply early in the legislative cycle.

Referred to the House Committee on Energy and Commerce.

2026-07-09

Source: Congress.gov

The Food and Drug Administration would be allowed to continue reviewing new drug and medical device applications even when the federal government runs out of money and shuts down, ensuring that life-saving medications and treatments don't get stuck in bureaucratic limbo during budget disputes. This would affect pharmaceutical companies waiting for approval of new drugs, patients who need access to innovative treatments, and the FDA staff who review these applications. The bill aims to prevent delays in getting new medicines to market whenever Congress fails to pass a budget on time.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

119 HR 9635 IH: Getting Innovations to Patients During Shutdowns Act U.S. House of Representatives 2026-07-09 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I119th CONGRESS2d SessionH. R. 9635IN THE HOUSE OF REPRESENTATIVESJuly 9, 2026Mr. Mullin introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo amend the Federal Food, Drug, and Cosmetic Act to establish special rules to provide for continued review of human drug and device submissions during a lapse of appropriations, and for other purposes. 1.Short titleThis Act may be cited as the Getting Innovations to Patients During Shutdowns Act. 2.Special rules to provide for continued review of human drug and device submissions during a lapse of appropriations (a)Human drug submissionsSection 736(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379h(e)) is amended— (1)by striking A human drug application and inserting the following: (1)In generalA human drug application; and (2)by adding at the end the following: (2)Special rule for lapse of appropriations (A)In generalNotwithstanding paragraph (1), during any period for which there is a lapse of appropriations for the programs and activities of the Food and Drug Administration, or for the collection of fees used to support the process for the review of drug applications, the Secretary— (i)may accept for filing an application or supplement described in paragraph (1) if the application or supplement is complete except for the payment of a fee required under subsection (a); and (ii)shall extend the deadline for the payment of such fee to the date that is 7 days after the last day of such period. (B)Effect of failure to pay fees on or before extended deadline dateIf the Secretary accepts an application or supplement subject to an extended deadline for the payment of a fee under subparagraph (A), and the person subject to the fee does not pay the fee on or before the date of the extended deadline— (i)the Secretary shall consider the application or supplement to be incomplete and deem the application or supplement not accepted; and (ii)in no case shall the Secretary clear, authorize, or approve the application or supplement (or any related application or supplement) until such fee is paid.. (b)Device submissionsSection 738(f)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j(f)(1)) is amended— (1)by striking A premarket application and inserting the following: (A)In generalA premarket application; and (2)by adding at the end the following: (B)Special rule for lapse of appropriations (i)In generalNotwithstanding subparagraph (A), during any period for which there is a lapse of appropriations for the programs and activities of the Food and Drug Administration, or for the collection of fees used to support the process for the review of device applications, the Secretary— (I)may accept a submission described in subparagraph (A) if the submission is complete except for the payment of a fee required under subsection (a)(2) or (a)(3) relating to the submission; and (II)shall extend the deadline for the payment of such fee to the date that is 7 days after the last day of such period. (ii)Effect of failure to pay fees on or before extended deadline dateIf the Secretary accepts a submission subject to an extended deadline for the payment of a fee under clause (i), and the person subject to the fee does not pay the fee on or before the date of the extended deadline— (I)the Secretary shall deem the submission not accepted; and (II)in no case shall the Secretary clear, authorize, or approve the submission (or any related submission)…

until such fee is paid..

• HR9478Methane Removal Research and Innovation Act of 2026
  Referred to Committee · 2026-06-25
• HR9291Federal Flood Risk Management Act of 2026
  Referred to Committee · 2026-06-11
• HR7985CHATBOT Act
  Referred to Committee · 2026-03-18
• HR7945Nitrous Oxide Safety Act of 2026
  Referred to Committee · 2026-03-16